CNTF and retinitis pigmentosa 1: In preclinical models and clinical trials, revakinagene taroretcel-lwey has demonstrated in vivo delivery rates of approximately 1.6 ng/day of CNTF,14 which has been shown to be sufficient for slowing photoreceptor degeneration in retinal degenerative diseases, including RP and MacTel.7